GSK's Blujepa met primary endpoints in phase 3 trials, showing 58.5% success in EAGLE-3 vs. 43.6% for nitrofurantoin in uUTI treatment. The FDA approved Blujepa for uUTIs in female adults and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback